News | September 14, 2011

ACC’s Appropriate Use Criteria Supported by Insurer for Cardiac Imaging Exams

September 14, 2011 – The Delaware Insurance Commissioner’s announcement that Blue Cross Blue Shield of Delaware (BCBSD) will support physicians’ use of an American College of Cardiology (ACC) program to make decisions about certain diagnostic imaging tests is a win for patients and a win for quality-of-care, said ACC CEO Jack Lewin, M.D.

Commissioner Karen Weldin Stewart on Tuesday announced an agreement with BCBSD that the company will pay for Delaware physicians to participate in the ACC’s online appropriate-use criteria-based program, FOCUS: Cardiovascular Imaging Strategies. The program supports physician decision-making and the use of best practices for decisions regarding cardiovascular diagnostic imaging. The agreement followed a state review of patient complaints about practices related to pre-authorization for nuclear cardiac imaging tests and concerns raised in the report about differences in criteria used by physician and insurers for nuclear cardiac imaging tests.

“In order to solve this problem, we need to get everyone on the same page as to when the studies are appropriate,” Stewart said in announcing the agreement. “With this new program, BCBSD is using the best criteria developed by the expert physicians, the American College of Cardiology, and will pay to have Delaware physicians using the best medical criteria.”  

FOCUS uses a computer-based tool developed by the ACC to help guide physicians when ordering imaging tests.  The tool applies nationally accepted, transparent and physician-developed appropriate use criteria to guide ordering of nuclear cardiac imaging tests. FOCUS allows local physicians to consistently apply appropriate use criteria to determine when patient tests are needed.  Importantly, the program provides feedback reports on the patterns of appropriate use to physician practices and health plans.  FOCUS participants then use the reports to complete action plans and share best practices.

“This decision is a win for patients and a win for evidence-based medicine,” Lewin said. “Commissioner Stewart and her staff should be commended for providing a solution that is based on physician-developed appropriate use criteria. This type of approach results in better care for patients and can ultimately save money. We hope Delaware will be a model for managing medical costs by focusing on patient-centered decision making and quality care.”

For more information: www.cardiosource.org/focus

 

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning.

Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning. (Images courtesy of Metrasens)

Feature | Magnetic Resonance Imaging (MRI) | July 03, 2018 | By Tobias Gilk
Nearly every job in the country is subject to certain health and safety regulations. Construction workers must wear...
Carestream DRX-Revolution Nano Mobile X-ray System

The Carestream DRX-Revolution Nano Mobile X-ray System.

Feature | Digital Radiography (DR) | July 03, 2018 | By Melinda Taschetta-Millane
The mobile digital radiography (DR) segment is the largest segment by product type in the global digital mobile DR...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
New U.S. Tariffs on Chinese Goods Include Imaging Equipment
News | Radiology Business | June 15, 2018 | Jeff Zagoudis, Associate Editor
The Office of the U.S. Trade Representative (USTR) released the much-anticipated list of Chinese-manufactured goods...
Overlay Init